Current role
Biotechnology · Healthcare
CEO, Board Member
2024-01-01–present
Nicholas A. Saccomano
Board Member
OnKure Therapeutics, Inc. (OKUR)Equibles does not estimate personal net worth.
Get an email with a short summary when OnKure Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get OKUR alertsAbout Nicholas A. Saccomano
Nicholas A. Saccomano is recorded as Board Member at OnKure Therapeutics, Inc. (OKUR) since January 1, 2024 and CEO at OnKure Therapeutics, Inc. (OKUR). The newest filing on record that lists Nicholas A. Saccomano as CEO and Board Member at OnKure Therapeutics, Inc. (OKUR) is dated April 21, 2026. OnKure Therapeutics, Inc. reported in an 8-K filed October 8, 2024 that Nicholas A. Saccomano was appointed President and Chief Executive Officer of OnKure, effective October 4, 2024. OnKure Therapeutics, Inc. reported in an 8-K filed May 13, 2024 that Nicholas A. Saccomano was appointed President and Chief Executive Officer. The proxy statement of OnKure Therapeutics, Inc. reports total compensation of $1,467,934 for Nicholas A. Saccomano in fiscal 2025, including a base salary of $600,000. Disclosed compensation is on record for 3 fiscal years. OnKure Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at OnKure Therapeutics, Inc. includes Nicholas A. Saccomano, Ph.D. (CEO), Nicholas Saccomano (CEO and Board Member), Andrew Phillips (Chairman and Board Member) and 7 others.
“The combined company will be led by Nicholas A. Saccomano, Ph.D. as President and Chief Executive Officer of OnKure.”
“Following the closing of the Proposed Transactions, Dr. Saccomano and Mr. Leverone will be named the President and Chief Executive Officer and Chief Financial Officer, respectively, of Reneo.”
Affiliation history
-
Current
2024-01-01–present
Last confirmed April 21, 2026
-
Current
Start not stated–present
Last confirmed April 21, 2026
Company network
Leadership on record at OnKure Therapeutics, Inc.
- Nicholas A. Saccomano, Ph.D. CEO
- Nicholas Saccomano CEO, Board Member
- Andrew Phillips Chairman, Board Member
- Jason Leverone CFO
- Jennifer P. Lam CFO
- Michael P. Cruse COO
- Andrew Philips, Ph.D. Board Member
- Continuing Directors Board Member
- Dr. Liam Ratcliffe Board Member
- Edward T. Mathers Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | OnKure Therapeutics, Inc. (OKUR) | President and Chief Executive Officer | $600,000 | $1,467,934 |
| 2024 | OnKure Therapeutics, Inc. (OKUR) | President and Chief Executive Officer | $462,145 | $9,515,165 |
| 2023 | OnKure Therapeutics, Inc. (OKUR) | President and Chief Executive Officer | $67,709 | $308,852 |